Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket ProtocolOctober 15, 2025 3:51 PM EDT | Source: Hemostemix Inc.Calgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated c ...

Hemostemix Files for Ethics Approval of its Study of Vascular DementiaOctober 09, 2025 9:03 AM EDT | Source: Hemostemix Inc.Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its Institutional Review Board (IRB) application for approval of its Phase 1 clinical trial titled "Treatment of Vascular Cognitive Impairment and Dementia with Angiogenic Cell Precursors (ACP-01)." Th ...